AstraZeneca Q3’25 Earnings Highlights

$AZN (+2,36 %)

🔹 Revenue: $15.19B (Est. $14.76B) 🟢

🔹 EPS: $2.38 (Est. $1.16) 🟢

Guidance (reiterated, CER):

🔹 FY25 Total Revenue: high single-digit % growth

🔹 FY25 Core EPS: low double-digit % growth